Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 2Urologic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Non-Hodgkin 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Adenoid Cystic 1

Interventions

fludarabine phosphate 36Whole-Body Irradiation 30Cyclophosphamide 30Mycophenolic Acid 28Azacitidine 27Tacrolimus 25Peripheral Blood Stem Cell Transplantation 24Busulfan 22Methotrexate 15Cyclosporine 15Antilymphocyte Serum 14Decitabine 11Cytarabine 11Melphalan 10fludarabine 9Radiotherapy 8Filgrastim 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cord Blood Stem Cell Transplantation 7thymoglobulin 6Sirolimus 6Rituximab 6Cyclosporins 6Clofarabine 6venetoclax 5merphos 5Sorafenib 4Lenalidomide 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Chronic × GSK-3326595 × Clear all
NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

GlaxoSmithKline

Phase 1/2 Terminated
30 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡